Medicine and Health Sciences Commons^™

Clinicopathological Significance Of Common Genetic Alterations In Patients With Acute Promyelocytic Leukemia, Sukanta Nath, Jina Bhattacharyya, Prem Chandra, Renu Saxena, Sudha Sazawal, Kandarpa Kumar Saikia

Hematology/Oncology and Stem Cell Therapy

Objective/Background: Acute myeloid leukemia (AML) is one of the common forms of hematological malignancy and acute promyelocytic leukemia (APL) is a unique subtype of AML conferring favorable prognosis. We aimed to determine the prevalence and prognostic impact of Fms-like tyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1) mutation, epidermal growth factor receptor (EGFR), and flow marker’s expression in patients with APL. Methods: In the present study, 165 de novo APL patients were molecularly characterized for promyelocytic leukemia (PML) breakpoint and additional genetic alterations. Reverse transcriptase polymerase chain reaction (PCR) and real time PCR assays were used to detect genetic alterations. Results: …

Serum Alpha-1-Antitrypsin Level In The Severity Prognosis Of Systemic Lupus Erythematosus Patients: Systematic Exploration Of Novel Biomarker, Supaporn Khamchun Dr., Chunyanuch Thakaeng Miss, Rattikan Na Lampang Miss

BioMedicine

Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affecting multi-organs injury and failure. The rapid, precision, and specificity prognosis by laboratory investigations could prevent active stage and severity in the disease.

Aims: To systematically explore and investigate the candidate serum protein for development into the novel biomarker for severity prognosis of SLE patients.

Methods: The proteins previously reported in abnormal level in serum/plasma of SLE patients since 2014-2020 were comprehensive collected. Thereafter, these serum proteins that found in other diseases were excluded. The association with molecules related to SLE severity of these candidate proteins were then …

Recurrence Score Testing Does Not Appear To Benefit Patients With Grade 1, Progesterone Receptor Positive Breast Cancers: An Opportunity To Eliminate Over-Treatment And Decrease Testing Costs, Udai S. Sibia, Thomas J. Sanders, Charles Mylander, Martin Rosman, Carol Tweed, Lorraine Tafra, Rubie S. Jackson

Hematology/Oncology and Stem Cell Therapy

Background: We previously described a risk prediction model (Anne Arundel Medical Center [AAMC] model) based on pathology which may eliminate the need for recurrence score (RS) testing in select early-stage breast cancers. There is a concern that patients in discordant risk prediction groups (AAMC vs. RS) may be overtreated or undertreated if RS testing were omitted. Methods: We queried the Surveillance, Epidemiology, and End Results (SEER) database for all breast cancer patients between 2004 and 2015. AAMC low-risk was defined as Grade 1 and progesterone receptor-positive (PR þ ) tumors, while AAMC high-risk was defined as Grade 3 or estrogen-negative …